Market revenue in 2024 | USD 810.8 million |
Market revenue in 2030 | USD 810.6 million |
Growth rate | 0.6% (CAGR from 2025 to 2030) |
Largest segment | Antivirals |
Fastest growing segment | Antifungals |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Antibacterials, Antivirals, Antifungals |
Key market players worldwide | Pfizer Inc, Abbott Laboratories, Gilead Sciences Inc, Bristol-Myers Squibb Co, Merck & Co Inc, Sandoz Group AG ADR, B. Braun, Novo Holdings, Mankind Pharma, Bayer AG, AstraZeneca PLC, Boehringer Ingelheim Pharma |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to anti-infective agents market will help companies and investors design strategic landscapes.
Antivirals was the largest segment with a revenue share of 50.84% in 2024. Horizon Databook has segmented the Saudi Arabia anti-infective agents market based on antibacterials, antivirals, antifungals covering the revenue growth of each sub-segment from 2018 to 2030.
The anti-infective agents market in Saudi Arabia is experiencing notable growth, driven by extensive government-led health initiatives and the expansion of the pharmaceutical sector. The Ministry of Health has implemented several key programs aimed at reducing infectious diseases, with a particular focus on tuberculosis (TB).
In addition, Saudi Arabia’s Vision 2030 framework emphasizes expanding the domestic pharmaceutical industry, supporting the development and local production of essential medicines, including antiinfective agents. This expansion not only reduces dependency on imports but also enhances access to innovative treatments.
The country is also fostering partnerships with international pharmaceutical companies, further boosting clinical research and local manufacturing capabilities. For instance, in January 2024, QIAGEN established its regional headquarters in Riyadh, Saudi Arabia, to expand its commercial presence in the region.
Horizon Databook provides a detailed overview of country-level data and insights on the Saudi Arabia anti-infective agents market , including forecasts for subscribers. This country databook contains high-level insights into Saudi Arabia anti-infective agents market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account